JP2017537084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537084A5 JP2017537084A5 JP2017525583A JP2017525583A JP2017537084A5 JP 2017537084 A5 JP2017537084 A5 JP 2017537084A5 JP 2017525583 A JP2017525583 A JP 2017525583A JP 2017525583 A JP2017525583 A JP 2017525583A JP 2017537084 A5 JP2017537084 A5 JP 2017537084A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- pharmaceutical composition
- composition according
- liver
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000012634 fragment Substances 0.000 claims description 13
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000012085 Endoglin Human genes 0.000 claims description 4
- 108010036395 Endoglin Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- 230000009693 chronic damage Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010047370 Vesicoureteric reflux Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 201000008618 vesicoureteral reflux Diseases 0.000 claims 1
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 40
- 235000004279 alanine Nutrition 0.000 description 20
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 15
- 150000001294 alanine derivatives Chemical class 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 10
- 239000004473 Threonine Substances 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 229960000310 isoleucine Drugs 0.000 description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 239000004474 valine Substances 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 150000003588 threonines Chemical class 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 150000002614 leucines Chemical class 0.000 description 4
- 150000002742 methionines Chemical class 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 2
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 2
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 2
- 101700032040 SMAD1 Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000011664 signaling Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078788P | 2014-11-12 | 2014-11-12 | |
| US62/078,788 | 2014-11-12 | ||
| PCT/US2015/060136 WO2016077451A1 (en) | 2014-11-12 | 2015-11-11 | Anti-endoglin antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537084A JP2017537084A (ja) | 2017-12-14 |
| JP2017537084A5 true JP2017537084A5 (OSRAM) | 2018-08-23 |
Family
ID=55954987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525583A Ceased JP2017537084A (ja) | 2014-11-12 | 2015-11-11 | 抗エンドグリン抗体及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10155820B2 (OSRAM) |
| JP (1) | JP2017537084A (OSRAM) |
| AU (1) | AU2015346444A1 (OSRAM) |
| CA (1) | CA2966905A1 (OSRAM) |
| IL (1) | IL251837A0 (OSRAM) |
| WO (1) | WO2016077451A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US9932386B2 (en) | 2011-04-20 | 2018-04-03 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CA2928708A1 (en) * | 2013-10-25 | 2015-04-30 | Acceleron Pharma, Inc. | Endoglin peptides to treat fibrotic diseases |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| DE112015006862T5 (de) * | 2015-08-31 | 2018-05-17 | Mitsubishi Electric Corporation | Anwendungsausführungsvorrichtung und Anwendungsausführungsverfahren |
| WO2018187158A1 (en) * | 2017-04-07 | 2018-10-11 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents |
| TW202019476A (zh) * | 2018-07-26 | 2020-06-01 | 日商參天製藥股份有限公司 | 伴隨視網膜纖維化之眼部疾病之藥劑 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025122587A2 (en) * | 2023-12-04 | 2025-06-12 | Normunity, Inc. | Anti-ly6k antibodies and methods of use |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US928641A (en) | 1908-10-09 | 1909-07-20 | Levi E Edmunds | Clasp for pilings. |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| ATE214075T1 (de) | 1996-05-31 | 2002-03-15 | Health Research Inc | Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie |
| US6190660B1 (en) | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| US5796097A (en) | 1997-03-05 | 1998-08-18 | California Lightwave Laboratories, Inc. | Chemical sensor and method |
| ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| MXPA03007316A (es) | 2001-02-19 | 2003-12-04 | Merck Patent Gmbh | Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida. |
| AU2002233343A1 (en) | 2001-02-20 | 2002-09-24 | Bayer Aktiengesellschaft | Human transient receptor potential channel protein. |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| CA2444483A1 (en) | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| EP1432447A2 (en) | 2001-09-27 | 2004-06-30 | The Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| US7115716B2 (en) | 2001-11-19 | 2006-10-03 | Eli Lilly And Company | Tumor specific monoclonal antibodies |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US7754884B2 (en) | 2005-01-03 | 2010-07-13 | Vanderbilt University | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging |
| US7691374B2 (en) | 2002-10-23 | 2010-04-06 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| US7097836B1 (en) | 2002-10-23 | 2006-08-29 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US7120987B2 (en) | 2003-08-05 | 2006-10-17 | Avery Dennison Corporation | Method of making RFID device |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101146909A (zh) | 2005-03-25 | 2008-03-19 | 格黎卡特生物技术股份公司 | 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| BRPI0615745A2 (pt) | 2005-09-12 | 2011-05-24 | Novimmune Sa | formulação de anticorpo anti-cd3 |
| US20070092577A1 (en) | 2005-10-03 | 2007-04-26 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| CA2663243A1 (en) | 2006-09-28 | 2008-04-03 | Merck Serono S.A. | Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| ES2827180T3 (es) | 2006-10-06 | 2021-05-20 | Amgen Inc | Formulaciones de anticuerpos estables |
| EP2125016A2 (en) | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
| US8748379B2 (en) | 2007-06-06 | 2014-06-10 | Research Development Foundation | RTEF-1 variants and the use thereof for inhibition of angiogenesis |
| JP5461402B2 (ja) | 2007-09-14 | 2014-04-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換三環式化合物およびその使用方法 |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| KR20100102152A (ko) | 2008-01-14 | 2010-09-20 | 제넨테크, 인크. | Ｅｇｆｌ8 길항제를 사용하여 혈관신생을 억제하는 방법 |
| CN102099491A (zh) | 2008-05-15 | 2011-06-15 | 北卡罗来纳-查佩尔山大学 | 调节血管生成的新靶标 |
| PT2350005E (pt) | 2008-08-29 | 2012-03-12 | Bayer Pharma AG | Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275) |
| AU2009294414A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies directed to CD105 and uses thereof |
| US8699361B2 (en) | 2008-09-30 | 2014-04-15 | Qualcomm Incorporated | Out-of-synchronization handling method and apparatus |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
| AU2010284433B2 (en) | 2009-08-17 | 2013-12-05 | Health Research, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US20180057602A1 (en) | 2009-08-17 | 2018-03-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| WO2012003470A2 (en) | 2010-07-02 | 2012-01-05 | Medimmune, Llc | Antibody formulations |
| US9932386B2 (en) | 2011-04-20 | 2018-04-03 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| EP3530275A1 (en) | 2011-08-01 | 2019-08-28 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CA2962277C (en) | 2013-09-20 | 2021-12-07 | Tufts Medical Center, Inc. | Methods and compositions for reducing cardiac damage and other conditions |
| GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2018067819A1 (en) | 2016-10-06 | 2018-04-12 | Tracon Pharmaceuticals, Inc. | Compositions and methods for treatment of cancers |
| WO2018187158A1 (en) | 2017-04-07 | 2018-10-11 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents |
-
2015
- 2015-11-11 US US15/520,020 patent/US10155820B2/en not_active Expired - Fee Related
- 2015-11-11 WO PCT/US2015/060136 patent/WO2016077451A1/en not_active Ceased
- 2015-11-11 JP JP2017525583A patent/JP2017537084A/ja not_active Ceased
- 2015-11-11 AU AU2015346444A patent/AU2015346444A1/en not_active Abandoned
- 2015-11-11 CA CA2966905A patent/CA2966905A1/en not_active Abandoned
-
2017
- 2017-04-20 IL IL251837A patent/IL251837A0/en unknown
-
2018
- 2018-07-17 US US16/037,282 patent/US10336831B2/en not_active Expired - Fee Related
- 2018-10-01 US US16/148,571 patent/US20190016815A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537084A5 (OSRAM) | ||
| US20210002353A1 (en) | Multi-valent hepatitis b virus antigen binding molecules and uses thereof | |
| JP2023085425A (ja) | 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体 | |
| JP2018535650A5 (OSRAM) | ||
| JP2016063812A5 (OSRAM) | ||
| JP2012504955A5 (OSRAM) | ||
| JP2010521147A5 (OSRAM) | ||
| JP2011528902A5 (OSRAM) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2017532048A5 (OSRAM) | ||
| JP2017113019A5 (OSRAM) | ||
| JP2011528901A5 (OSRAM) | ||
| JP2015522252A5 (OSRAM) | ||
| JP2016529229A5 (OSRAM) | ||
| JP2017500018A5 (OSRAM) | ||
| JP2020509031A5 (OSRAM) | ||
| JP7527386B2 (ja) | 新型コロナウイルスのヒトモノクローナル抗体およびその使用 | |
| JP2019506839A5 (OSRAM) | ||
| RU2016134256A (ru) | Антитела против f гликопротеина вирусов хендра и нипах | |
| JP2018529661A5 (OSRAM) | ||
| JP2005520523A5 (OSRAM) | ||
| JP2016006052A5 (OSRAM) | ||
| JP2013539354A5 (OSRAM) | ||
| JP2018537117A5 (OSRAM) |